Adding treatment with pembrolizumab to standard of care in patients with advanced soft tissue sarcoma of the limb appears to significantly improve disease-free survival, researchers reported on Nov…. read more.
There is a lung cancer screening test that is saving lives – and yet most people who could be getting the test have never heard of it or… read more.
Quitting smoking within six months after a cancer diagnosis adds an average of two years to a patient’s life. With this information in hand, all cancer centers have… read more.
Rigel Pharmaceuticals, Inc. announced it is issuing a Dear Health Care Provider (DHCP) letter related to a new safety signal for Gavreto (pralsetinib) after consultation with the FDA…. read more.
After falling short in a confirmatory clinical trial, Gilead Sciences has decided to withdraw Trodelvy (sacituzumab goviteca-hziy) as a bladder cancer treatment in the U.S. Gilead Sciences announced… read more.
Although breast cancer is the most common non-skin cancer diagnosed in women, finding support during treatment and through survivorship can be incredibly challenging. An analysis of posts from… read more.
Bayer announced the submission of an application to the European Medicines Agency (EMA) for the oral androgen receptor inhibitor (ARi) darolutamide. Bayer is seeking approval for the use… read more.
An investigative immunotherapy regimen for advanced Hodgkin lymphoma has increased the survival rate from 80 percent to 92 percent, researchers reported on Oct. 17, 2024 in the NEJM/New… read more.
Janssen-Cilag International NV, a Johnson & Johnson company, announced the submission of a Type II variation application to the European Medicines Agency (EMA) seeking approval for an indication… read more.
A new study led by researchers at Queen Mary University of London reveals women would welcome the option to choose between self-sampling and traditional screening done by a… read more.
AbbVie announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing authorization of mirvetuximab soravtansine… read more.
An ultrasound test that detected 96% of ovarian cancers in postmenopausal women should replace current standard of care test in the UK according to a new study. In… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
